• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Epinomics, Parker Institute to collaborate for cancer immunotherapy at Stanford University

Epinomics, Parker Institute to collaborate for cancer immunotherapy at Stanford University

February 10, 2017
CenterWatch Staff

Researchers from Epinomics will collaborate with the research team led by Crystal Mackall, M.D., director of the Parker Institute for Cancer Immunotherapy at Stanford, to utilize biomarkers defined by Epinomics’ immune intelligence framework to improve outcome and reduce adverse events in immunotherapy clinical trials.

"The insights from this work will serve to direct further improvements for these therapeutics that will be pursued at Stanford and the set of biomarkers will be employed in clinical use moving forward," said Fergus Chan, MBA, who co-founded Epinomics in 2013. "Joining forces with Dr. Mackall and her team at Stanford will enable us to bring precision medicine to these immunotherapies."

The Parker Institute for Cancer Immunotherapy at Stanford University opened in April thanks to a grant from the Parker Foundation, which was started by entrepreneur Sean Parker. "We are very excited to be collaborating with Epinomics," Dr. Mackall said. “I know we will benefit greatly from the expertise Epinomics has in the epigenomics field, including their analytics platform that is advancing therapeutic development efforts and discovery of biomarkers for use in clinical care for immuno-oncology applications.”

The epigenome ("the living genome") refers to any modification to the genome without changes to the DNA sequence, and it regulates what genes are turned on and off. If the genome, which shows what genes we have, is the hardware of our bodies, then epigenome is the software programming layer of our bodies. Because the epigenome dynamically responds to the environment and reflects one's current health state, it holds the key to personalized medicine.

Paul Giresi, Ph.D., another co-founder of Epinomics, noted that immunotherapy has been shown to be a promising approach for the effective treatment of cancer, including achieving long term remission in patients who have not responded to existing therapies. But to date there is no gold standard for the application or monitoring for this type of therapy.

“The key to unlocking this potential in immuno-oncology has been the development of a new technology for reading the epigenome and creation of a deep analytics framework that serves as a central intelligence hub for understanding immune function in human health and disease. Using this framework can derive measures (biomarkers) of immune function across both healthy baseline samples and disease to enable investigators to pinpoint the key immunological features that are the drivers of human disease and are predictive of clinical outcomes," Dr. Giresi said.

Upcoming Events

  • 16Feb

    Fundamentals of FDA Inspection Management: Reduce Anxiety, Increase Inspection Success

  • 21May

    WCG MAGI Clinical Research Conference – 2023 East

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • SurveywBlueBackground-360x240.png

    Sites Name Tech Acceptance as Essential Factor in Selection of Sponsors, Survey Finds

  • TrendsInsights2023-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Two

  • TimeMoneyEffort-360x240.png

    Time is Money and So Is Effort, Budgeting Experts Say

  • TrendsInsights2023A-360x240.png

    WCG Clinical Research Trends and Insights for 2023, Part Three

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell or Share My Data

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing